Our People.

Experience that matters.

The Team.

Looking beyond the obvious.

Our team is experienced and driven. Having done it ourselves, we understand what it takes to start and develop a product.

Natalie McNamee
Director

Natalie McNamee

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015. She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis. Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters. She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer. Quanticel was acquired by Celgene for $485M in 2015. Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Director

William McNamee

William has been a Director of Tarnagulla Ventures Pty Ltd since 2016. During his time he has also co-founded and led the development on three life sciences companies, Holman Pharmaceuticals, Dalmoral Pharmaceuticals, and LimRad Therapeutics. Prior to this he was VP of Business Development at Premneo Pharmaceuticals, a clinical stage rare disease company. William started his career at Goldman Sachs Group in New York in the Securities division and has a B.A. in Economics from Harvard University.

William McNamee

looking for investors?

If you are working on a new promising medical therapy and looking for capital investment to help you get to the market, we would love to get introduced.